Absstract of: US2022387614A1

The present invention provides a glycoconjugate for administration to a subject in a method comprising the steps of: (i) administering a first dose of glycoconjugate; (ii) subsequently administering a second dose of glycoconjugate; wherein the amount of glycoconjugate in the first dose or first and second doses are atypically low, and also related aspects.

Absstract of: US2022387574A1

The present disclosure relates to Salmonella Gallinarum mutant strains and uses thereof. A vaccine composition according to an aspect has no risk of recovering pathogenicity, has no residual pathogenicity due to detoxification of an endotoxin, and does not cause lesions and bacterial re-isolation, thereby exhibiting significantly improved safety compared to the existing fowl typhoid vaccines. In addition, since the vaccine composition induces a high-level immune response even when administered to young chicks, it may be used regardless of age, and as the vaccine strain may be used as a live vaccine having an excellent protective capability by itself, the vaccine composition may be useful for preventing and alleviating fowl typhoid.

Absstract of: US2022387574A1

The present disclosure relates to Salmonella Gallinarum mutant strains and uses thereof. A vaccine composition according to an aspect has no risk of recovering pathogenicity, has no residual pathogenicity due to detoxification of an endotoxin, and does not cause lesions and bacterial re-isolation, thereby exhibiting significantly improved safety compared to the existing fowl typhoid vaccines. In addition, since the vaccine composition induces a high-level immune response even when administered to young chicks, it may be used regardless of age, and as the vaccine strain may be used as a live vaccine having an excellent protective capability by itself, the vaccine composition may be useful for preventing and alleviating fowl typhoid.

Absstract of: US2022387574A1

The present disclosure relates to Salmonella Gallinarum mutant strains and uses thereof. A vaccine composition according to an aspect has no risk of recovering pathogenicity, has no residual pathogenicity due to detoxification of an endotoxin, and does not cause lesions and bacterial re-isolation, thereby exhibiting significantly improved safety compared to the existing fowl typhoid vaccines. In addition, since the vaccine composition induces a high-level immune response even when administered to young chicks, it may be used regardless of age, and as the vaccine strain may be used as a live vaccine having an excellent protective capability by itself, the vaccine composition may be useful for preventing and alleviating fowl typhoid.

Absstract of: US2022387574A1

The present disclosure relates to Salmonella Gallinarum mutant strains and uses thereof. A vaccine composition according to an aspect has no risk of recovering pathogenicity, has no residual pathogenicity due to detoxification of an endotoxin, and does not cause lesions and bacterial re-isolation, thereby exhibiting significantly improved safety compared to the existing fowl typhoid vaccines. In addition, since the vaccine composition induces a high-level immune response even when administered to young chicks, it may be used regardless of age, and as the vaccine strain may be used as a live vaccine having an excellent protective capability by itself, the vaccine composition may be useful for preventing and alleviating fowl typhoid.

Absstract of: WO2022248917A1

The invention refers to a method for simultaneous detection and quantification of Listeria monocytogenes, Salmonella spp. and Shiga toxin-producing Escherichia coli (STEC), from any kind of sample related to food production, including complex food matrices such as fish, meat, or fruit; or simple matrices such as water, or food contact surfaces. The method of invention allows specific quantification of the above-mentioned pathogens simultaneously thanks to specificity of designed primers for the qPCR reaction. It is also highly reliable because the method includes a system to adequately control the quantification of pathogens within the matrix. This system comprises the inoculation of samples with a known concentration of a transformed microorganism (host) carrying a chimeric sequence, acting as an internal control host for the whole process.

Absstract of: US2022378853A1

The methods described herein are for treating infections in individuals having cancer and who are receiving cancer immunotherapy, preferably employing a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and thereafter, administering an immune checkpoint inhibitor thereto. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa, Klebsiella bacteria, Staphylococcus aureus; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; Clostridium; Neisseria gonnorrhoea; Acinetobacter baumannii; and Campylobacter bacteria and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Enterococcus, Fusobacterium, Coprococcus, LactoBacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, and F. prausnitzii. The CRISPR system may include Cas9, Cpf1 and Cas3, and may be delivered using a bacteriophage.

Absstract of: US2022378051A1

The invention provides combinations of bacteriophages for use in reducing and preventing growth of Salmonella enterica and Escherichia coli.

Absstract of: WO2021125982A1

Attenuated, non-pathogenic strain of Salmonella enteritidis 3934Vac DwaaL of rough phenotype, modified to express the xenoantigen of the capsid protein (CAP) of porcine circovirus type 2 (PCV-2), and the method for obtaining said modified strain of Salmonella enteritidis. Also disclosed is a recombinant, effective and innocuous live anti-PCV-2 vaccine for pigs, developed using a process comprising the insertion and integration of the xenoantigen of the CAP of PCV-2 into the chromosome or plasmid of the attenuated, non-pathogenic strain of Salmonella enteritidis 3934Vac DwaaL.

Absstract of: WO2018006034A1

Provided are conjugates including a targeting moiety that binds to a cell surface molecule of a target cell and a target cell surface-editing enzyme. Also provided are compositions and kits that include the conjugates, as well as methods of using the conjugates. Methods of making conjugates are also provided.

Absstract of: WO2022245142A1

The present invention relates to a kit for the simultaneous differential diagnosis of typhoid fever and paratyphoid fever infections, comprising typhoid and paratyphoid antigens, a diagnostic composition, and a method for diagnosing typhoid fever and paratyphoid fever by using same. When the kit for the simultaneous differential diagnosis of typhoid fever and paratyphoid fever infections, according to the present invention, is used, the presence or absence of typhoid fever and paratyphoid fever infections can be more accurately differentiated and diagnosed simultaneously.

Absstract of: MY194292A

An extract of an herbal composition comprising at least two different dried plants useful as antimicrobial and/or antibiofilm agent in the treatment or prevention of microbial infections caused by bacteria, such as for example Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus or Staphylococcus, or by fungi, such as for example is herein described. It has been found that in such extract, the active ingredients exert their biological effects in a synergistic manner. The extract may constitute the active ingredient of a food supplement, a nutraceutical, pharmaceutical or cosmetic composition or a functional food or a food additive. A process for preparing said extract is also described here.

Absstract of: WO2021189226A1

A method of taking a skin sample can include placing an adhesive onto a portion of skin and lifting the adhesive from the skin. A skin sample may then be tested while still on the adhesive, for example, by inoculating the sample with a bacterium, fungus, virus, or a combination.

Absstract of: US2022372116A1

The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.

Absstract of: WO2022245142A1

The present invention relates to a kit for the simultaneous differential diagnosis of typhoid fever and paratyphoid fever infections, comprising typhoid and paratyphoid antigens, a diagnostic composition, and a method for diagnosing typhoid fever and paratyphoid fever by using same. When the kit for the simultaneous differential diagnosis of typhoid fever and paratyphoid fever infections, according to the present invention, is used, the presence or absence of typhoid fever and paratyphoid fever infections can be more accurately differentiated and diagnosed simultaneously.

Absstract of: WO2022241579A1

The invention relates to an antibacterial formulation comprising a mixture of bacteriophages that have lytic activity against Salmonella spp. strains, and a carrier, pH stabiliser and/or pharmaceutically and veterinarily acceptable excipients. This formulation is useful for the prevention and treatment of infectious diseases caused by Salmonella spp. and different serovars. The invention also relates to a use and method for preventing or treating infectious diseases caused by Salmonella spp. in breeding animals which comprises orally administering the antibacterial formulation to a non-human animal.

Absstract of: EP3378485A1

The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.

Absstract of: CN115350274A

本发明属于药物制剂领域，涉及一种长度可控的鞭毛纳米纤维的制备及其作为黏膜佐剂的应用。该制剂以菌体分离出的鞭毛纤维作为黏膜佐剂，采用探头超声技术实现对纤维长度的调控。通过体外细胞实验，证明了鞭毛纳米纤维在不造成细胞毒性的前提下，能诱导先天免疫细胞TLR5的活化，以及线粒体活性氧的产生，并进一步鉴定NLRP3和NLRC4炎性体可以被该制剂活化，阐明了细胞因子IL‑1β的产生机制。通过体内动物实验，进一步证明对鞭毛纳米纤维佐剂长度的调控可以实现对黏膜免疫反应的调控，并证明了长度是鞭毛蛋白纳米纤维穿透黏液层的关键因素。同时，鞭毛蛋白纳米纤维通过黏膜免疫的方式可促进细胞免疫的产生，并发挥抗肿瘤功效。

Absstract of: AU2021265090A1

In a general aspect, microorganisms [e.g., bacteria, etc.) are identified and detected. In some examples, a liquid solvent is supplied through a first channel of a sampling probe to an internal reservoir of the sampling probe; a fixed volume of the liquid solvent in the internal reservoir is held in direct contact with a sample surface for a period of time to form a liquid analyte; gas is supplied to the internal reservoir through a second channel of the sampling probe; the liquid analyte is extracted from the internal reservoir through a third channel of the sampling probe; the liquid analyte is transferred to a mass spectrometer; the mass spectrometer processes the liquid analyte to produce mass spectrometry data; and the mass spectrometry data are analyzed to detect and identify a microorganism [e.g., bacteria, fungi, or another type of microorganism) present at the sample surface.

Absstract of: CN115340997A

本发明公开一种基于Lpp引导序列靶向呈递和高效表达外源抗原的重组沙门菌构建方法，利用同源重组方法将大肠杆菌Lpp引导序列引入到本实验室前期构建的pS‑SaoA质粒中，形成重组表达质粒pS‑Lpp‑SaoA，在猪霍乱沙门菌载体菌株rSC0016中引入pS‑Lpp‑SaoA质粒，形成重组猪霍乱沙门菌rSC0016（pS‑Lpp‑SaoA）；外源抗原SaoA在该菌株及其OMVs中可以高效表达和靶向呈递，免疫小鼠后可产生强大的体液免疫和细胞免疫，并产生高水平的细胞因子，保护小鼠免受猪链球菌致死剂量的攻击；本发明为无佐剂OMVs疫苗平台提供了一种有前景的通用策略，具有较大的市场应用潜力和潜在的经济效益。

Absstract of: KR20220150636A

본 발명은 장알균 부착 재조합 단백질을 유효성분으로 포함하는 장알균 검출용 조성물에 대한 것이다. 장알균을 신속 정확하게 진단하는 것은 장알균에 의한 질병의 치료 및 예방 차원에서 매우 중요하다. 본 발명의 재조합 단백질은 장알균에 대하여 우수한 특이 부착능을 갖고 있다. 따라서 여러 감염질환의 원인이 되는 장알균을 간단하고 신속히 진단할 수 있는 재조합 형광단백질은 관련 보건산업에 활용될 가치가 높다.

Absstract of: WO2018106754A1

A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.

Absstract of: AU2021235152A1

The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being: - devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and - substituted at position C6' of the non-reducing end of their lipid A domain by a hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group. It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject.

Absstract of: US2022354919A1

An extract of an herbal composition comprising at least two different dried plants useful as antimicrobial and/or antibiofilm agent in the treatment or prevention of microbial infections caused by bacteria, such as for example Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus or Staphylococcus, or by fungi, such as for example is herein described. It has been found that in such extract, the active ingredients exert their biological effects in a synergistic manner. The extract may constitute the active ingredient of a food supplement, a nutraceutical, pharmaceutical or cosmetic composition or a functional food or a food additive. A process for preparing said extract is also described here.

Absstract of: AU2021250442A1

The present invention relates to a DNA vaccine comprising a